Corporate Secretary, TransCelerate
VP, Clinical Program Design and Exploratory Medicine/Pharmacology, Eli Lilly and Company
Robert has been at Lilly for 20 years in various roles across Development, Drug Safety, and Medical Affairs, including various previous vice president roles: leading Phase 2B-4 Development for Psychiatry, Pain, and Sleep; leading Global Medical Affairs (including strategic accountability for assets outside Diabetes and Oncology plus oversight of the Medical Teams in Lilly’s US, Canada, Australia, and European Affiliates); and leading Global Patient Safety for the clinical portfolio. He has served as Co-Chair of PhRMA’s Clinical and Pre-Clinical Development Committee and as a work group leader for TransCelerate’s pharmacovigilance efforts. Currently Robert is the industry representative to FDA’s Psychopharmacologic Drugs Advisory Committee.
Prior to joining Lilly, Dr. Baker spent a dozen years as an Academic Psychiatrist studying schizophrenia and substance abuse. He completed medical school at Northwestern University and psychiatry training at the University of Pittsburgh.